Welcome to our dedicated page for Veru news (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru stock.
Veru Inc. develops late clinical-stage biopharmaceutical programs for cardiometabolic and inflammatory diseases. Company news centers on clinical development of enobosarm, an oral selective androgen receptor modulator being studied with GLP-1 receptor agonist therapy to make weight reduction more selective for fat loss while preserving lean mass, physical function, and bone.
Recurring updates also cover sabizabulin, an oral microtubule disruptor being developed for chronic inflammation related to atherosclerotic cardiovascular disease. Veru’s announcements commonly include fiscal results, business updates, clinical-study progress, regulatory feedback, scientific presentations, and conference webcasts tied to its small-molecule pipeline.
Veru (NASDAQ:VERU) reported fiscal 2026 Q2 results and progress in its enobosarm obesity program. Research and development expenses fell to $3.1 million from $3.9 million, and general and administrative expenses to $4.1 million from $5.2 million.
Operating loss from continuing operations decreased to $7.2 million from $8.1 million, and net loss to $2.7 million, or $0.12 per share, from $7.9 million, or $0.54 per share. Cash rose to $27.6 million from $15.8 million. The Phase 2b PLATEAU trial in older obese patients on semaglutide is actively enrolling, with interim DXA-based data expected in early 2027 and topline data in late 2027, building on positive Phase 2b QUALITY results.
Veru (NASDAQ: VERU) will report fiscal 2026 second quarter financial results and provide a business update on Wednesday, May 13, 2026 at 8:00 a.m. ET. The company will host a conference call and audio webcast; replay options will be available online and by telephonic replay.
Access the live webcast and archived replay via the Home or Investors page at verupharma.com. Telephone dial-in numbers and replay passcode are provided for domestic and international callers.
Veru (NASDAQ: VERU) enrolled the first patient in the Phase 2b PLATEAU trial testing oral enobosarm 3mg plus injectable semaglutide in ~200 older patients (age ≥65, BMI ≥35) with obesity to preserve lean mass, physical function and bone while augmenting fat and weight loss.
An interim DXA analysis is expected in Q1 2027 (34 weeks) and final topline data in Q4 2027 (primary endpoint: percent change in total body weight at 68 weeks).
Veru (NASDAQ: VERU) announced that Mitchell Steiner, M.D., Chairman, President and CEO, will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 from 3:20 pm to 3:50 pm ET.
A live webcast will be accessible via the company website and an archived webcast will be posted after the event.
Veru (NASDAQ: VERU) reported Q1 fiscal 2026 results and clinical updates. Cash was $33.0M as of Dec 31, 2025. Operating loss improved to $5.4M and net loss was $5.3M ($0.26/share).
Veru plans a ~200-patient Phase 2b PLATEAU trial of enobosarm plus semaglutide starting Q1 2026 with an interim analysis planned Q1 2027; FDA provided regulatory pathways including a 5% placebo-corrected weight-loss benchmark or alternative functional/BMD benefits.
Veru (NASDAQ: VERU) will report fiscal 2026 first quarter results and host a conference call and audio webcast on Wednesday, February 11, 2026 at 8:00 a.m. ET.
The webcast is accessible via the company's website; teleconference dial‑in numbers and replay details are provided. An archived webcast will be available for approximately three months; a telephonic replay will be available for one week.
Veru (NASDAQ: VERU) reported fiscal 2025 results and clinical progress for enobosarm in obesity on Dec 17, 2025. Key clinical highlights include FDA regulatory clarity that a ≥5% placebo‑corrected incremental weight loss at 52 weeks or smaller weight difference with clinically meaningful physical function benefit may support approval. Phase 2b PLATEAU (enobosarm 3 mg + GLP‑1 RA) is planned to start Q1 2026 with interim analysis expected Q1 2027. Fiscal 2025 results: cash $15.8M (9/30/25), R&D $15.6M, operating loss $24.8M; company completed a post‑period public offering for ~$23.4M net proceeds.
Veru (NASDAQ: VERU) will report fiscal year 2025 financial results and provide a business update on Wednesday, December 17, 2025 at 8:00 a.m. ET. The company will host a conference call and live audio webcast accessible from the Home and Investors pages at www.verupharma.com. A replay of the webcast will be archived on the company website for approximately three months. A telephonic replay will be available from about 12:00 p.m. ET for one week by dialing the provided replay numbers with passcode 2225332.
Veru (NASDAQ: VERU) will present multiple times at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and the SCWD Regulatory and Clinical Trials Update Workshop in Rome, Italy on December 11–13, 2025. Mitchell Steiner, Veru’s Chairman, President & CEO, is the company presenter.
Key sessions include: a workshop discussion on treatment approaches and regulatory issues for muscle wasting during obesity therapy (Dec 11, 10:15–11:15 CET and 11:15–11:55 CET), a presentation on weight loss drugs and cardiovascular health (Dec 12, 16:30–16:45 CET), and a roundtable on novel sarcopenia strategies while treating obesity including an update on Enobosarm (Dec 13, 10:00–10:15 CET). Locations: A. Roma Lifestyle Hotel, Hall A.
Veru (NASDAQ: VERU) will present two abstracts at ObesityWeek 2025 in Atlanta, November 4-7, 2025.
Poster: "Enobosarm Reduced Body Weight and Fat Regain and Preserved Lean Mass After Discontinuing Semaglutide" presented by Steven B. Heymsfield, M.D., on Tuesday, November 4, 2025, 7:30 pm–8:30 pm ET in Exhibit Hall A1. Oral: "Enobosarm in Combination With GLP-1RA is Selective for Fat Loss While Preserving Lean and Function" presented by Mitchell Steiner, M.D., on Friday, November 7, 2025, 8:00 am–8:15 am ET in GWCC Building A: A411-A412.
Additional meeting details are available at https://obesityweek.org/.